Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795392

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795392

Vaccine Research

PUBLISHED:
PAGES: 172 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Vaccine Research Market to Reach US$73.8 Billion by 2030

The global market for Vaccine Research estimated at US$39.4 Billion in the year 2024, is expected to reach US$73.8 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2024-2030. Public Vaccine Research, one of the segments analyzed in the report, is expected to record a 12.3% CAGR and reach US$51.8 Billion by the end of the analysis period. Growth in the Private Vaccine Research segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.4 Billion While China is Forecast to Grow at 10.0% CAGR

The Vaccine Research market in the U.S. is estimated at US$10.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.9% and 8.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Vaccine Research Market - Key Trends & Drivers Summarized

Why Is Vaccine Research a Strategic Priority in Global Health and Biomedical Science?

Vaccine research has become a critical pillar of modern biomedical science, directly influencing public health outcomes, pandemic preparedness, and the global response to infectious diseases. With the world still recovering from the profound impacts of the COVID-19 pandemic, the spotlight on vaccine research has intensified, underscoring the need for agile, science-driven innovation to counter both existing and emerging pathogens. Historically, vaccine development was a slow and labor-intensive process, often taking a decade or more to bring a product to market. However, the urgency of recent global health crises has accelerated timelines, mobilized unprecedented funding, and fostered collaborative frameworks between governments, academia, and the pharmaceutical industry. These developments have elevated vaccine research from a reactive to a proactive endeavor. Today, vaccines are being investigated not only for infectious diseases like influenza, measles, and HIV, but also for non-infectious conditions such as cancer, autoimmune diseases, and addiction. As the world becomes more interconnected and urbanized, the risks associated with rapid pathogen transmission are growing, making vaccines one of the most cost-effective and powerful tools in disease prevention. Moreover, global health equity goals are increasingly dependent on the development of affordable, stable, and scalable vaccines for low-income regions. Vaccine research is therefore no longer just a scientific or clinical undertaking but a global imperative that supports health security, economic resilience, and social stability.

How Are Scientific and Technological Advances Transforming the Vaccine Research Landscape?

The vaccine research landscape is undergoing a transformative shift, driven by a wave of scientific and technological breakthroughs that are expanding the limits of what is possible in disease prevention. One of the most revolutionary advancements is the rise of mRNA vaccine platforms, which proved their efficacy during the COVID-19 crisis and are now being explored for other infectious and non-infectious diseases. This platform allows for rapid design and production, adaptability to new strains, and scalable manufacturing, making it ideal for pandemic response. Additionally, viral vector technologies, recombinant protein subunits, and nanoparticle-based delivery systems are enabling researchers to develop more targeted and effective vaccines with fewer side effects. Structural biology and computational modeling are allowing scientists to design antigens with unprecedented precision, increasing immunogenicity and reducing development risks. Adjuvant innovation is also enhancing immune responses, especially in populations such as the elderly or immunocompromised. Genomic and proteomic technologies are providing deeper insights into pathogen evolution and host-pathogen interactions, guiding the design of next-generation vaccines. Artificial intelligence and machine learning are being integrated into early-stage research to identify vaccine targets, predict efficacy, and simulate immune responses. High-throughput screening, automation, and synthetic biology are reducing development timelines and production costs. Together, these innovations are not only improving vaccine performance but also opening the door to custom, multivalent, and even universal vaccines capable of protecting against a broad array of related pathogens.

Which Institutions and Geographies Are Driving Global Vaccine Research Efforts?

Global vaccine research efforts are being powered by a network of leading institutions, biotech companies, academic research centers, and government bodies that collectively span the globe. In North America, organizations such as the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and numerous universities have long led vaccine development efforts in collaboration with private firms like Pfizer, Moderna, and Johnson & Johnson. Europe is also a strong hub, with institutions such as the European Medicines Agency (EMA), the University of Oxford, and numerous German biotech companies contributing to research on novel vaccine platforms and manufacturing processes. In Asia, China and India have rapidly expanded their vaccine R&D capabilities, with institutions like the Chinese Academy of Sciences, Bharat Biotech, and the Serum Institute of India leading large-scale clinical trials and global vaccine distribution. Japan and South Korea are also investing heavily in biopharmaceutical innovation, including next-generation vaccines for chronic and rare diseases. Global coalitions such as Gavi, CEPI (Coalition for Epidemic Preparedness Innovations), and the World Health Organization play a central role in coordinating international research efforts, funding trials in lower-income countries, and ensuring equitable vaccine access. Moreover, collaborative research projects funded through multinational initiatives and philanthropic foundations like the Bill & Melinda Gates Foundation are helping bridge regional disparities and accelerate development timelines. These cross-sector and cross-border partnerships are vital in ensuring that vaccine research benefits from shared knowledge, resources, and global strategic alignment.

What Factors Are Driving Growth and Investment in the Vaccine Research Market?

The growth in the vaccine research market is driven by a convergence of public health needs, commercial opportunity, technological readiness, and global policy initiatives. One of the most prominent drivers is the increased frequency and severity of infectious disease outbreaks, which has created a sustained urgency for new vaccines that can be developed and deployed rapidly. Anticipation of future pandemics and the re-emergence of diseases once thought under control are prompting governments and global health organizations to invest in vaccine innovation as a critical component of national and international preparedness plans. At the same time, demographic trends such as aging populations, growing urbanization, and global travel are expanding the population vulnerable to infections, reinforcing the need for broader immunization strategies. The rising incidence of antimicrobial resistance has also intensified the search for preventive solutions like vaccines to reduce reliance on antibiotics. On the commercial side, the success of blockbuster vaccines has demonstrated the financial viability of vaccine R&D, attracting venture capital, pharmaceutical partnerships, and institutional funding into the sector. Technological advancements, such as the validation of mRNA platforms and scalable biomanufacturing techniques, have de-risked investment and encouraged rapid product development. Additionally, policy support in the form of fast-track regulatory pathways, advanced market commitments, and funding incentives is further stimulating innovation. These combined forces are creating a robust and rapidly expanding vaccine research market that is central not only to public health outcomes but also to the future of biomedical science and global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Vaccine Research market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Public Vaccine Research, Private Vaccine Research); Age Group (Pediatric Age Group, Adult Age Group)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AstraZeneca
  • Bavarian Nordic
  • BioNTech SE
  • Bharat Biotech
  • CSL Limited
  • CureVac AG
  • Dynavax Technologies
  • Emergent BioSolutions
  • GlaxoSmithKline (GSK)
  • Inovio Pharmaceuticals
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India
  • Sinovac Biotech
  • Takeda Pharmaceutical
  • Valneva SE

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38298

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Vaccine Research - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Pandemic Preparedness Throws the Spotlight on Scalable and Rapid Vaccine Research Platforms
    • Surge in Government and Philanthropic Funding Spurs Acceleration of Early-Stage Vaccine Development
    • Here's How mRNA and Next-Gen Platform Technologies Are Transforming the Vaccine R&D Landscape
    • Increased Focus on Zoonotic and Emerging Pathogens Strengthens the Business Case for Broad-Spectrum Vaccine Candidates
    • Advancements in AI and Computational Biology Propel Growth in Antigen Discovery and Immunogenicity Prediction
    • Here's the Story: How Modular Clinical Trial Designs Are Streamlining Vaccine Research Timelines
    • Rising Demand for Universal and Multivalent Vaccines Expands the Scope of Multi-Pathogen Research Initiatives
    • Technological Progress in Adjuvants and Delivery Systems Enables Improved Efficacy and Dose Sparing
    • Growth in Oncology and Therapeutic Vaccines Opens New Avenues for Personalized Vaccine Research
    • Decentralized and Remote Trial Models Sustain Research Continuity Amid Global Health Disruptions
    • Equity and Global Access Considerations Drive Interest in Heat-Stable and Low-Cost Vaccine Formulations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Vaccine Research Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Public Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Public Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Public Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Private Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Private Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Private Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Pediatric Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Adult Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • JAPAN
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • CHINA
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • EUROPE
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Vaccine Research by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Vaccine Research by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • FRANCE
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • GERMANY
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Rest of Europe 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Asia-Pacific 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of World Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of World 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!